Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 2Subcutaneous panniculitis-like T-cell lymphoma 1Sarcoma 1Mediastinal Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Intracranial Germ Cell Tumors 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

VAP-cyclo protocol 2Gemcitabine 2apatinib 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Lenalidomide 1Ifosfamide 1Etoposide 1Dexamethasone 1Cisplatin 1Asparaginase 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lymphoma, T-Cell, Peripheral × Ifosfamide × Clear all
NCT03071822 2018-06-11

Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

The University of Hong Kong

Phase 4 Unknown
50 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡